Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eye examination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    263 result(s) found for: Eye examination. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-003005-21 Sponsor Protocol Number: cloROP-2021 Start Date*: 2021-12-10
    Sponsor Name:Region Örebro län
    Full Title: Klonidin as pain relief in eye examination of premature infants - cloROP
    Medical condition: Pain during eye examination of premature infants.
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005694-31 Sponsor Protocol Number: 2012/ADE002 Start Date*: 2013-07-05
    Sponsor Name:Adenovir Pharma AB
    Full Title: Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Mult...
    Medical condition: Acute phase Adenoviral-induced Epidemic Keratoconjunctivitis, EKC
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10014975 Epidemic keratoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004271-12 Sponsor Protocol Number: NGF0213 Start Date*: 2014-01-17
    Sponsor Name:Dompé s.p.a
    Full Title: An open-label study evaluating safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops at different doses in patients with Dry Eye
    Medical condition: Dry Eye syndrome is caused by either decreased tear production or increased tear film evaporation. Dry eye is a chronic inflammatory condition of the ocular surface with severe symptoms and visual ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10013777 Dry eye syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005621-30 Sponsor Protocol Number: 541 Start Date*: 2008-07-03
    Sponsor Name:BAUSCH&LOMB
    Full Title: A multicenter, Investigator - masked, parallel-group, randomized study of the efficacy and safety of loteprednol etabonate 0.5% eyedrops versus dexamethasone 0.1% eyedrops in the treatment of ocula...
    Medical condition: Subjects scheduled to undergo cataract surgery
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000937-54 Sponsor Protocol Number: MC2-03-C1 Start Date*: 2015-08-03
    Sponsor Name:DRUG DELIVERY SOLUTIONS ApS (PART OF MC2 BIOTEK GROUP)
    Full Title: A phase II, multicenter, randomized, double-masked, 4 parallel arms, controlled 6-month trial designed to evaluate the safety and efficacy of PAD ciclosporin (CsA 0.06% and 0.03%) ophthalmic disper...
    Medical condition: ocular dryness (Dry Eye Disease - DED)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014904 10013778 Dry eyes LLT
    20.0 100000014904 10013777 Dry eye syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) NO (Completed) AT (Completed) ES (Completed) PT (Completed) FR (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-007872-40 Sponsor Protocol Number: ROPP-2008-01 Start Date*: 2014-08-19
    Sponsor Name:Premacure AB, A member of the Shire Group of Companies
    Full Title: Determination of the rhIGF-I/rhIGFBP-3 Dose; Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-I Levels within Physiological Levels in Premature Infan...
    Medical condition: Retinopathy of Prematurity (ROP)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) IT (Completed) NL (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-005160-18 Sponsor Protocol Number: RP101-200 Start Date*: 2018-12-18
    Sponsor Name:Redwood Pharma AB
    Full Title: A Phase II, multicentre, randomised, placebo-controlled, double-masked trial of RP101 ophthalmic formulation versus vehicle in post-menopausal women with moderate to severe dry eye syndrome
    Medical condition: moderate or severe dry eye syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10013774 Dry eye PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001708-19 Sponsor Protocol Number: SVS20-EUR-06-01 Start Date*: 2008-02-21
    Sponsor Name:TRB CHEMEDICA INTERNATIONAL SA
    Full Title: A 3-month study of the efficacy and safety of SVS20 in patients with bilateral moderate dry eye syndrome : A prospective, double-masked, randomised, controlled, parallel-group, 3-arm, multicentre, ...
    Medical condition: treatment on bilateral moderate dry eye syndrome due to Sjögren's syndrome or diagnosed as a primary syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013774 Dry eye LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003253-36 Sponsor Protocol Number: LBS-008-CT03 Start Date*: Information not available in EudraCT
    Sponsor Name:Belite Bio, Inc
    Full Title: Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects
    Medical condition: Stargardt Disease
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004857-15 Sponsor Protocol Number: SYL1001_III Start Date*: 2015-05-07
    Sponsor Name:Sylentis
    Full Title: DOSE-FINDING STUDY TO ASSESS THE SAFETY AND EFFECT OF SYL1001 IN PATIENTS WITH OCULAR PAIN
    Medical condition: Patients with eye pain associated to dry eye
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002823-46 Sponsor Protocol Number: LT4030-201 Start Date*: 2018-09-11
    Sponsor Name:Laboratoires THÉA; Research and Development Department
    Full Title: Efficacy and safety assessment of T4030 eye drops (unpreserved fixed combination of bimatoprost 0.01% and timolol 0.1% or 0.5%) versus Ganfort® UD (Unit Dose) in ocular hypertensive or glaucomatous...
    Medical condition: Glaucoma, ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) PL (Completed) HU (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002439-14 Sponsor Protocol Number: SHP640-301 Start Date*: Information not available in EudraCT
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine...
    Medical condition: Adenoviral Conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10001257 Adenoviral conjunctivitis PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) EE (Prematurely Ended) HU (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000747-27 Sponsor Protocol Number: 049/SI Start Date*: 2020-09-09
    Sponsor Name:SOCIETÀ INDUSTRIA FARMACEUTICA ITALIANA (SIFI) SPA
    Full Title: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase II Study to evaluate the Safety and Efficacy of Pro-ocular™ 0.5% and 1% in Patients with Dry Eye Syndrome
    Medical condition: Dry Eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film and accompanied by ocular symptoms, in which tear film instability, hyperosmolarity...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004853 10013777 Dry eye syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002910-29 Sponsor Protocol Number: BECRO/PHN/LATANO Start Date*: 2017-09-26
    Sponsor Name:PHARMATHEN
    Full Title: Therapeutic Equivalence (non-inferiority), Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic Preservative-Free Formulation ...
    Medical condition: Open angle glaucoma or ocular hypertension.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    20.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004524-29 Sponsor Protocol Number: BECRO/PHN/LATIM Start Date*: 2018-02-28
    Sponsor Name:PHARMATHEN
    Full Title: Therapeutic Equivalence (non-inferiority), Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic Preservative-Free Formulation ...
    Medical condition: Open angle glaucoma or ocular hypertension.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    20.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-017388-41 Sponsor Protocol Number: LT1225-PII-06/09 Start Date*: 2010-01-14
    Sponsor Name:Laboratoires Théa
    Full Title: Efficacy and Safety Assessment of Azyter® eye drops (T1225) in patients with blepharitis
    Medical condition: Patients with blepharitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000465-17 Sponsor Protocol Number: CHL.3-02-2019 Start Date*: 2020-06-16
    Sponsor Name:Sintetica S.A.
    Full Title: A Phase II/III, Randomized, Double-Masked, Vehicle-Controlled, Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in healthy volunteers
    Medical condition: healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10024758 Local anaesthesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000182-31 Sponsor Protocol Number: CHDR1438 Start Date*: 2015-02-11
    Sponsor Name:CHDR
    Full Title: A randomized, double-blind, placebo-controlled, cross-over study to assess the effects of fampridine on eye movements and nerve conduction in patients with multiple sclerosis (MS) and a unilateral ...
    Medical condition: Multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004409-42 Sponsor Protocol Number: LRP/LUBT010/2016/008 Start Date*: 2020-11-23
    Sponsor Name:Lupin Limited (Biotechnology Division)
    Full Title: A Global, Phase III, Double Blind, Randomized Controlled Study to Compare the Efficacy, Safety & Immunogenicity of LUBT010 with Lucentis® in Patients with Neovascular Age-Related Macular Degeneration
    Medical condition: Neovascular Age Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-005486-13 Sponsor Protocol Number: 12-EI-0134 Start Date*: 2013-02-25
    Sponsor Name:The National Eye Institute
    Full Title: A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema (CADME)
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 03 04:19:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA